Pall Life Sciences wins BPI 2016 Best Downstream Application Award
Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.
Pall Life Sciences, a division of Pall Corporation,has won the BioProcess International (BPI) Award for best downstream processing application for the Cadence Acoustic Separator. Celebrated bi-annually since 2012, the BPI Awards are hosted during the BioProcess International Conference in Boston, MA. The awards exist to celebrate outstanding individual and team achievements that allow the industry to deliver better, more effective treatments to a global patient base.
Based on acoustic wave separation technology licensed from FloDesign Sonics, the Cadence Acoustic Separator was launched in early 2016 as a novel single-use solution for the clarification of cell culture bioprocess fluids. The system is a robust platform technology that enables continuous cell separation without centrifugation and dramatically reduced filtration steps for cost-effective preconditioning of the clarified cell culture fluid for downstream processes. The technology can also be fully integrated with Pall’s portfolio of continuous downstream bioprocessing technologies.
“We are honored by the recognition of the Cadence Acoustic Separator in 2016, but it is particularly exciting to win this award,” said Michael Egholm, VP & General Manager of Pall Biopharmaceuticals. “We first introduced the concept of acoustic wave separation for biopharmaceutical applications at last year’s BPI 2015 conference, with the intention of launching in 2016. Thank you to my team, and the team at FloDesign Sonics for partnering with us to develop and launch such a game-changing technology.”
Earlier this year, the Cadence Acoustic Separator technology was awarded second prize for Innovation in an open vote on submitted posters at the Recovery of Biological Products XVII Conference in Bermuda, as well as featured in Pharmaceutical Manufacturing as a 2016 Star Innovation.
The Cadence Acoustic Separator technology is on display in booth 521 at BPI 2016 this week, among a portfolio of enabling Pall Life Sciences technologies. The displays demonstrate scale up for the clarification application, and a process development approach for perfusion with the AWS technology. Both applications are set to be launched in 2017.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...